News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
CARMAT SAS Sets $89.81 Million IPO to Fund Artificial Heart on July 13
July 8, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS, July 7 (Reuters) - French artificial heart developer Carmat, which counts EADS (EAD.PA) amongst its shareholders, has set the date of its initial public offering for July 13 as it seeks extra funds to bring its product to market.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Europe
MORE ON THIS TOPIC
IPO
Swiss ADC Biotech Takes SPAC Track to NASDAQ
April 23, 2025
·
1 min read
·
Annalee Armstrong
Deals
Genentech Offers up to $765M in Biobucks to Repertoire for I&I Drug Discovery
April 23, 2025
·
1 min read
·
Dan Samorodnitsky
Deals
Unusual New Fund Launches to Unlock Some $30B of Capital ‘Trapped’ in Public Biotechs
April 18, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer
April 16, 2025
·
1 min read
·
Dan Samorodnitsky